Verastem Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw $18.7M in net product revenue and expanding prescriber adoption, with the LGSOC franchise expected to be self-sustaining in H2 2026. R&D advanced with new phase II trials for VS-7375, and cash runway extends into H1 2027.
-
Sales growth and broad adoption continue for the lead therapy, with strong reimbursement and long patient duration. Key clinical trials are progressing, including a pivotal confirmatory study and promising results for the G12D inhibitor, with major data updates expected mid-year.
Fiscal Year 2025
-
Delivered $30.9M net product revenue in 2025 post-FDA approval, with strong CO-PACK adoption and expanding prescriber base. Cash runway extends into 2027, with LGSOC franchise expected to be self-sustaining in H2 2026. Robust clinical pipeline and prudent capital management support future growth.
-
Avutometinib's launch in low-grade serous ovarian cancer is progressing well, with academic and community uptake growing as infrastructure matures. The G12D inhibitor shows best-in-class potential, with strong efficacy and tolerability, and pivotal trial readouts expected in 2027.
-
Strong commercial launch and clinical progress for avutometinib-defactinib in ovarian cancer, with expansion into pancreatic and lung cancer through a promising G12D inhibitor collaboration. Key regulatory, clinical, and commercial milestones are expected in the coming year.
-
Strong commercial momentum in LGSC is supported by targeted distribution and growing community uptake. RAMP 301 trial enrollment was slightly increased, with high confidence in both KRAS mutant and wild-type success. VS-7375 shows best-in-class efficacy, and U.S. trials are leveraging rapid Chinese data.
-
Q3 2025 saw $11.2M in net product revenue from a strong AVMAPKI FAKZYNJA CO-PACK launch, with broad adoption across academic and community settings. R&D and SG&A investments drove a $39.4M net loss, but cash reserves provide runway into 2026. Multiple clinical milestones are expected in 2026.
-
Accelerated FDA approval and strong early sales for the lead ovarian cancer therapy highlight commercial momentum, while robust clinical data in pancreatic and lung cancer support pipeline expansion. Financial runway extends into 2026, with strategic focus on partnerships and further clinical milestones.
-
A novel dual therapy for low-grade serous ovarian cancer achieved early approval and rapid market uptake, with broad reimbursement and inclusion in NCCN guidelines pending. Pipeline assets show high response rates in KRAS-driven cancers, supporting strong future growth.
-
FDA approval and launch of AVMAPKI FAKZYNJA CO-PACK drove $2.1M in early revenue, with strong uptake across academic and community settings. Financials reflect increased R&D and SG&A for launch, and cash reserves support operations into 2026. Broad payer coverage and positive provider feedback position for continued growth.
-
Recent milestones include early FDA approval for ovarian cancer, strong PDAC data, and a robust launch strategy. G12D inhibitor shows promise in multiple cancers, with U.S. trials set to begin and global regulatory progress ongoing.
-
Recent data highlight strong efficacy and manageable safety for AVMAPKI FAKZYNJA in ovarian and pancreatic cancers, with the RAMP 205 trial showing an 83% response rate. The KRAS G12D inhibitor VS-7375 demonstrated robust preclinical and early clinical results, supporting rapid trial expansion.
-
Early FDA approval for a novel combination therapy in low-grade serous ovarian cancer sets the stage for a $3B addressable market, with a focused launch strategy and strong engagement with providers and patients. NCCN guideline submission and upcoming ASCO data are key near-term catalysts.
-
Accelerated FDA approval of the lead therapy has driven a strong early launch, with high physician engagement and broad KRAS testing already in place. International expansion is underway, and promising pipeline data in pancreatic and lung cancers will be presented at ASCO. Cash reserves support operations into late 2026.
-
Priority review for avutometinib/defactinib in LGSOC is underway, with FDA decision expected summer 2025. Strong clinical data and robust commercial preparations support a $4B market opportunity, while pipeline expansion in pancreatic cancer and KRAS-driven tumors offers multiple catalysts in 2025.
Fiscal Year 2024
-
Lead combination therapy in LGSOC shows strong efficacy, especially in KRAS mutant patients, with a 22-month median PFS and a favorable safety profile. Market potential exceeds $3 billion, and expansion into lung and pancreatic cancers is underway, with key data updates expected next year.
-
Lead program targets RAS pathway in LGSOC, showing improved efficacy and tolerability over current options. NDA submission is complete, with launch expected mid next year and strong commercial preparations underway. Market opportunity is significant, with rapid uptake anticipated at launch.
-
The RAMP 201 phase II trial of avutametnib plus defactinib in recurrent LGSOC showed a 31% ORR (44% in KRAS mutant, 17% in wild-type), durable responses, and a favorable safety profile in heavily pretreated patients. Regulatory submission for accelerated approval is on track, with broad physician and patient enthusiasm for rapid adoption.
-
The company is advancing a combination therapy for LGSOC, with pivotal data and a rolling NDA submission expected to culminate by year-end. Early pipeline results in pancreatic cancer and KRAS-targeted therapies show promise, supporting a multi-billion dollar market opportunity and a focused commercialization strategy.